Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)]
Teva Pharma GmbH
Healthy
1 trial -
StemEx®
Teva Pharma GmbH
Hematologic Malignancies
1 trial -
Synthetic Conjugated estrogens, B
Teva Pharma GmbH
Menopause
1 trial -
TEV-45779
Teva Pharma GmbH
Chronic Urticaria
1 trial -
TEV-50717
Teva Pharma GmbH
Cerebral Palsy, Dyskinetic
2 trials -
TEV-50717
Teva Pharma GmbH
Tourette Syndrome
3 trials -
TEV-56248
Teva Pharma GmbH
Asthma
2 trials -
TV-1106
Teva Pharma GmbH
Growth Hormone-Deficiency
4 trials -
TV-44749
Teva Pharma GmbH
Schizophrenia
3 trials -
TV-46000
Teva Pharma GmbH
Schizophrenia
2 trials -
TV-46763
Teva Pharma GmbH
Pain
1 trial -
TVB-009
Teva Pharma GmbH
Osteoporosis, Postmenopausal
1 trial -
Tacrolimus BID
Teva Pharma GmbH
Medication Adherence
1 trial -
Tapinarof Cream 1%
Teva Pharma GmbH
Plaque Type Psorisis
1 trial -
Tbo-filgrastim
Teva Pharma GmbH
Healthy Participants
1 trial -
Trifarotene 0.005 % Topical Cream
Teva Pharma GmbH
Acne Vulgaris
1 trial -
albuterol aerosol by HFA MDI
Teva Pharma GmbH
Exercise-induced Bronchospasm
1 trial -
beclomethasone dipropionate (QVAR)
Teva Pharma GmbH
Asthma
1 trial -
bendamustine
Teva Pharma GmbH
Non-Hodgkin's Lymphoma
2 trials -
custirsen sodium
Teva Pharma GmbH
Castrate-Resistant Prostate Cancer
1 trial -
cyclobenzaprine hydrochloride
Teva Pharma GmbH
Chronic Migraine
1 trial -
levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets
Teva Pharma GmbH
Dysmenorrhea
2 trials -
lipegfilgrastim
Teva Pharma GmbH
Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia
1 trial -
non-pegylated liposomal doxorubicin
Teva Pharma GmbH
Tubular Breast Cancer Stage II
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources